KRISTIN LUTZ: Open Payments
NPI 1639826852 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$489 in 22 payments from 11 companies in 2025. Trend: 2023 $721 · 2024 $396 · 2025 $489
Food & beverage: $489
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $123 |
| ABBVIE INC. | 4 | $89 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Exact Sciences Corporation | 2 | $45 |
| Astellas Pharma US Inc | 2 | $43 |
| Merck Sharp & Dohme LLC | 1 | $31 |
| Lilly USA, LLC | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
Products named: Wegovy, GEMTESA, The Cologuard Plus Collection Kit, Veozah, VRAYLAR, UBRELVY, CAPVAXIVE, Ozempic.
Industry payments across MD — which companies pay providers there.
